Clinical Trials List
2024-01-06 - 2026-04-30
Phase III
Recruiting1
Terminated2
ICD-10C34.80
Malignant neoplasm of overlapping sites of unspecified bronchus and lung
ICD-10C34.81
Malignant neoplasm of overlapping sites of right bronchus and lung
ICD-10C34.82
Malignant neoplasm of overlapping sites of left bronchus and lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.8
Malignant neoplasm of other parts of bronchus or lung
-
Trial Applicant
Syneos Health
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- 林宗哲 Division of Hematology & Oncology
- 黃得瑞 Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- 吳尚俊 Division of General Internal Medicine
- JIN-YUAN SHIH Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 王逸熙
- 林理涵
- 陳友木 Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
- 李易濰
- 張晃智
- Chia-Cheng Tseng Division of Thoracic Medicine
- 賴建豪 Division of Thoracic Medicine
- 林孟志
- 郭明濬 Division of Hematology & Oncology
- 黃國棟 Division of Thoracic Medicine
- 鍾聿修 Division of Thoracic Medicine
- Shau-Hsuan Li
- 陳彥豪 Division of Hematology & Oncology
- 趙東瀛 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5 participants
-
Global
705 participants
